Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

U.S. tariffs on Canada have put experts at odds over how appropriate the action was, particularly given the unaddressed ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD in postmenopausal women with T2D.

Big pharma’s interest in rare diseases will continue ... with former FDA Commissioner Scott Gottlieb and ARCH Venture Partners co-founder Bob Nelson both suggesting that the regulatory ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

In many cases big pharma companies like to hedge their bets ... are strong – but it still meant sharing profits with an arch-rival. We’ll never know for sure but from the outside it looks ...

S&P 500 E-Mini futures (ESH25) are down -0.90%, andMarch Nasdaq 100 E-Mini futures (NQH25) are down -1.04% this morning, ...

S&P 500 E-Mini futures (ESH25) are trending up +0.56% this morning as investors gear up for the release of crucial U.S.

There are numerous career options for science students. They can enrol in courses in the general scientific stream, engineering, or medicine. However, the most popular technical undergraduate degree ...